hepatitis b vaccine (recombinant)

Hepatitis B vaccine (recombinant) is a non-infectious subunit viral vaccine derived from the surface antigen of the hepatitis B virus (HBsAg). Produced using recombinant DNA technology, typically in yeast (Saccharomyces cerevisiae) or mammalian cells, the vaccine contains purified HBsAg proteins that assemble into virus-like particles. While traditionally used for the active immunization (prophylaxis) against infection caused by all known subtypes of HBV, it is also being explored as a therapeutic vaccine. In the context of the INTER-HBV trial, it is evaluated for its ability to stimulate humoral immunity (anti-HBs production) in chronic hepatitis B patients who have achieved HBsAg seroclearance but maintain low antibody titers following pegylated interferon therapy.